COMET-Studie: ADOPTIVE IMMUNTHERAPIE MIT ANTIKÖRPERN Rekonvaleszentenplasma zur Therapie von COVID-19 zur Vermeidung schwerer Krankheitsverläufe Die Situation eines Pandemieausbruchs eines neu auftret

ACT-COVID19: ADOPTIVE IMMUNOTHERAPY WITH T CELLS A Phase I/ Randomized Phase II Trial To Analyse Safety And Efficacy Of Human SARS-COV-2-Specific T Lymphocyte Transfer In Patients With COVID-19 In Nee

Allo-EBT: EBV-specific T cells to treat PTLD (Phase I/II Trial) Safety evaluation of allogeneic HLA-matched EBV-specific T cells (EBV-CTLs) in children and adults with advanced EBV-associated post-tra

CurePML: HPyV2-specific T cells to treat PML (Phase II Trial) Allogeneic HPyV 2 specific T cell therapy in patients with progressive multifocal leukoencephalopathy Sponsor: Hannover Medical School Car

Saad Samman Consultant E-Mail: Samman.saad(at)mh-hannover.de

Country information Information on the various countries can be found at the DAAD or the Federal Foreign Office . Reports on the offers can be found here. University collaborations The MHH maintains c

01.11.2025 Add-on Fellowship for Interdisciplinary Life Science at the Joachim Herz Foundation The Joachim Herz Stiftung supports up to 80 scientists from engineering, economics, and life sciences thr

Nephrology colloquium On February 24 Organization: Clinical Department of Nephrology and Hypertension, Hannover Medical School Dear colleagues, We look forward to an interesting exchange. Yours sincer